Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 3/2017

01-03-2017 | Research Article

Incidence and survival time trends for Spanish children and adolescents with leukaemia from 1983 to 2007

Authors: R. Marcos-Gragera, J. Galceran, C. Martos, A. L. de Munain, M. Vicente-Raneda, C. Navarro, J. R. Quirós-Garcia, M.-J. Sánchez, E. Ardanaz, M. Ramos, A. Mateos, D. Salmerón, S. Felipe, R. Peris-Bonet

Published in: Clinical and Translational Oncology | Issue 3/2017

Login to get access

Abstract

Objective

We have analysed incidence and survival trends of children and adolescents with leukaemia registered in Spanish population-based cancer registries during the period 1983–2007.

Methods

Childhood and adolescent leukaemia cases were drawn from the 11 Spanish population-based cancer registries. For survival, registries with data for the period 1991–2005 and follow-up until 31-12-2010 were included. Overall incidence trends were evaluated using joinpoint analysis. Observed survival rates were estimated using Kaplan–Meier, and trends were tested using the log-rank test.

Results

Based on 2606 cases (2274 children and 332 adolescents), the overall age-adjusted incidence rate (ASRw) of leukaemia was 47.9 cases per million child-years in children and 23.8 in adolescents. The ASRw of leukaemia increased with an annual percentage change of 9.6 % (95 % CI: 2.2–17.6) until 1990 followed by a stabilisation of rates. In adolescents, incidence did not increase. Five-year survival increased from 66 % in 1991–1995 to 76 % in 2001–2005. By age, survival was dramatically lower in infants (0) and adolescents (15−19) than in the other age groups and no improvement was observed. In both children and adolescents, differences in 5-year survival rates among major subgroups of leukaemias were significant.

Conclusions

The increasing incidence trends observed in childhood leukaemias during the study period were confined to the beginning of the period. Remarkable improvements in survival have been observed in Spanish children with leukaemias. However, this improvement was not observed in infants and adolescents.
Literature
1.
Coebergh JW, Reedijk AM, de Vries E, Martos C, Jakab Z, Steliarova-Foucher E, et al. Leukaemia incidence and survival in children and adolescents in Europe during 1978–1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):2019–36.CrossRefPubMed
2.
Linet MS, Ries LA, Smith MA, Tarone RE, Devesa SS. Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst. 1999;91(12):1051–8.CrossRefPubMed
3.
Marcos-Gragera R, Cervantes-Amat M, Vicente ML, de Sanjose S, Guallar E, Godoy C, et al. Population-based incidence of childhood leukaemias and lymphomas in Spain (1993–2002). Eur J Cancer Prev. 2010;19(4):247–55.CrossRefPubMed
4.
Maule MM, Zuccolo L, Magnani C, Pastore G, Dalmasso P, Pearce N, et al. Bayesian methods for early detection of changes in childhood cancer incidence: trends for acute lymphoblastic leukaemia are consistent with an infectious aetiology. Eur J Cancer. 2006;42(1):78–83.CrossRefPubMed
5.
Pollan M, Lopez-Abente G, Ardanaz E, Moreo P, Moreno C, Vergara A, et al. Childhood cancer incidence in Zaragoza and Navarre (Spain): 1973–1987. Eur J Cancer. 1997;33(4):616–23.CrossRefPubMed
6.
Hjalgrim LL, Rostgaard K, Schmiegelow K, Soderhall S, Kolmannskog S, Vettenranta K, et al. Age- and sex-specific incidence of childhood leukaemia by immunophenotype in the Nordic countries. J Natl Cancer Inst. 2003;95(20):1539–44.CrossRefPubMed
7.
Dreifaldt AC, Carlberg M, Hardell L. Increasing incidence rates of childhood malignant diseases in Sweden during the period 1960–1998. Eur J Cancer. 2004;40(9):1351–60.CrossRefPubMed
8.
McNally RJ, Birch JM, Taylor GM, Eden OB. Incidence of childhood precursor B-cell acute lymphoblastic leukaemia in north-west England. Lancet. 2000;356(9228):485–6.CrossRefPubMed
9.
McNally RJ, Alexander FE, Birch JM. Space-time clustering analyses of childhood acute lymphoblastic leukaemia by immunophenotype. Br J Cancer. 2002;87(5):513–5.CrossRefPubMedPubMedCentral
10.
van Duijn CM, van Steensel-Moll HA, Coebergh JW, van Zanen GE. Risk factors for childhood acute non-lymphocytic leukaemia: an association with maternal alcohol consumption during pregnancy? Cancer Epidemiol Biomarkers Prev. 1994;3(6):457–60.PubMed
11.
Ma X, Metayer C, Does MB, Buffler PA. Maternal pregnancy loss, birth characteristics, and childhood leukaemia (United States). Cancer Causes Control. 2005;16(9):1075–83.CrossRefPubMed
12.
13.
Brenner H, Coebergh J, Parkin D, Izarzugaza I, Clavel J, Arndt V, et al. Up-to-date monitoring of childhood cancer long-term survival in Europe: leukaemias and lymphomas. Ann Oncol 2007;18(9):1561–68.
14.
Peris-Bonet R, Salmeron D, Martinez-Beneito MA, Galceran J, Marcos-Gragera R, Felipe S, et al. Childhood cancer incidence and survival in Spain. Ann Oncol. 2010;21(Suppl 3):iii103–10.PubMed
15.
Navarro C, Martos C, Ardanaz E, Galceran J, Izarzugaza I, Peris-Bonet R, et al. Population-based cancer registries in Spain and their role in cancer control. Ann Oncol. 2010;21(Suppl 3):iii3–13.PubMed
16.
Frit A, Jack A, Percy C, Shanmugaratnam K, Sobin L, Parkin M, et al. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organisation; 2000.
17.
Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood cancer, third edition. Cancer. 2005;103(7):1457–67.CrossRefPubMed
18.
19.
20.
Stiller CA, Marcos-Gragera R, Ardanaz E, Pannelli F, Almar ME, Canada MA, et al. Geographical patterns of childhood cancer incidence in Europe, 1988-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):1952–60.CrossRefPubMed
21.
Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–51.CrossRefPubMed
22.
23.
Esteve J, Benhamou E, Croasdale M, Raymond L. Relative survival and the estimation of net survival: elements for further discussion. Stat Med. 1990;9(5):529–38.CrossRefPubMed
24.
Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5–a population-based study. Lancet Oncol. 2014;15(1):35–47.CrossRefPubMed
25.
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977;35(1):1–39.CrossRefPubMedPubMedCentral
26.
Stiller CA. Childhood cancer in Britain. New York: Oxford University Press; 2007.CrossRef
27.
Coebergh JW, der Does-van Van, den Berg, van Wering ER, van Steensel-Moll HA, Valkenburg HA, van’t Veer MB, et al. Childhood leukaemia in The Netherlands, 1973–1986: temporary variation of the incidence of acute lymphocytic leukaemia in young children. Br J Cancer. 1989;59(1):100–5.CrossRefPubMedPubMedCentral
28.
Dalmasso P, Pastore G, Zuccolo L, Maule MM, Pearce N, Merletti F, et al. Temporal trends in the incidence of childhood leukaemia, lymphomas and solid tumors in north-west Italy, 1967–2001. A report of the Childhood Cancer Registry of Piedmont. Haematologica. 2005;90(9):1197–204.PubMed
29.
Magnani C, Dalmasso P, Pastore G, Terracini B, Martuzzi M, Mosso ML, et al. Increasing incidence of childhood leukaemia in Northwest Italy, 1975–98. Int J Cancer. 2003;105(4):552–7.CrossRefPubMed
30.
Shah A, Coleman MP. Increasing incidence of childhood leukaemia: a controversy re-examined. Br J Cancer. 2007;97(7):1009–12.PubMedPubMedCentral
31.
McWhirter WR, Dobson C, Ring I. Childhood cancer incidence in Australia, 1982–1991. Int J Cancer. 1996;65(1):34–8.CrossRefPubMed
32.
Xie Y, Davies SM, Xiang Y, Robison LL, Ross JA. Trends in leukaemia incidence and survival in the United States (1973–1998). Cancer. 2003;97(9):2229–35.CrossRefPubMed
33.
Desandes E, Clavel J, Berger C, Bernard JL, Blouin P, De LL, et al. Cancer incidence among children in France, 1990–1999. Pediatr Blood Cancer. 2004;43(7):749–57.CrossRefPubMed
34.
Steliarova-Foucher E, Stiller C, Kaatsch P, Berrino F, Coebergh JW. Trends in childhood cancer incidence in Europe, 1970–99. Lancet. 2005;365(9477):2088.CrossRefPubMed
35.
Freedman MH, Estrov Z, Chan HS. Juvenile chronic myelogenous leukaemia. Am J Pediatr Hematol Oncol. 1988;10(3):261–7.CrossRefPubMed
36.
Niemeyer CM, Kratz CP. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. Br J Haematol. 2008;140(6):610–24.CrossRefPubMed
37.
Niemeyer CM, Baumann I. Myelodysplastic syndrome in children and adolescents. Semin Hematol. 2008;45(1):60–70.CrossRefPubMed
38.
Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukaemia. Nat Genet. 2010;42(9):794–800.CrossRefPubMedPubMedCentral
39.
Kramarova E, Stiller CA. The international classification of childhood cancer. Int J Cancer. 1996;68(6):759–65.CrossRefPubMed
40.
Li J, Thompson TD, Miller JW, Pollack LA, Stewart SL. Cancer incidence among children and adolescents in the United States, 2001–2003. Pediatrics. 2008;121(6):e1470–7.CrossRefPubMed
41.
Lacour B, Guyot-Goubin A, Guissou S, Bellec S, Desandes E, Clavel J. Incidence of childhood cancer in France: National Children Cancer Registries, 2000–2004. Eur J Cancer Prev. 2010;19(3):173–81.CrossRefPubMed
42.
Kaatsch P, Spix C. German Childhood Cancer Registry-annual report 2011 (1980–2010). Institute for Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz. 2012. http://​www.​kinderkrebsregis​ter.​de.
43.
AIRTUM Working Group. Italian cancer figures, report 2012: Cancer in children and adolescents 21. Epidemiol Prev 2013;37(1)Suppl 1:1–296.
44.
45.
Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, et al. Survival of European children and young adults with cancer diagnosed 1995–2002. Eur J Cancer. 2009;45(6):992–1005.CrossRefPubMed
46.
Gatta G, Luksch R, Coleman MP, Corazziari I. Survival from acute non-lymphocytic leukaemia (ANLL) and chronic myeloid leukaemia (CML) in European children since 1978: a population-based study. Eur J Cancer. 2001;37(6):695–702.CrossRefPubMed
47.
Coebergh JW, Pastore G, Gatta G, Corazziari I, Kamps W. Variation in survival of European children with acute lymphoblastic leukaemia, diagnosed in 1978–1992: the EUROCARE study. Eur J Cancer. 2001;37(6):687–94.CrossRefPubMed
48.
Pastore G, Viscomi S, Gerov GL, Terracini B, Madon E, Magnani C. Population-based survival after childhood lymphoblastic leukaemia in time periods corresponding to specific clinical trials from 1979 to 1998–a report from the Childhood Cancer Registry of Piedmont (Italy). Eur J Cancer. 2003;39(7):952–60.CrossRefPubMed
49.
Stiller CA, Eatock EM. Patterns of care and survival for children with acute lymphoblastic leukaemia diagnosed between 1980 and 1994. Arch Dis Child. 1999;81(3):202–8.CrossRefPubMedPubMedCentral
50.
Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukaemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood. 2012;119(1):34–43.CrossRefPubMedPubMedCentral
51.
Pieters R, Schrappe M, De LP, Hann I, De RG, Felice M, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370(9583):240–50.CrossRefPubMed
52.
Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukaemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012;30(14):1663–9.CrossRefPubMedPubMedCentral
53.
Gatta G, Rossi S, Foschi R, Trama A, Marcos-Gragera R, Pastore G, et al. Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukaemia from 1982 to 2002. Haematologica. 2013;98(5):744–52.CrossRefPubMedPubMedCentral
54.
Ribera JM, Ribera J, Genesca E. Treatment of adolescent and young adults with acute lymphoblastic leukaemia. Mediterr J Hematol Infect Dis. 2014;6(1):e2014052.CrossRefPubMedPubMedCentral
55.
Patrick K, Wade R, Goulden N, Mitchell C, Moorman AV, Rowntree C, et al. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2014;166(3):421–4.CrossRefPubMed
56.
Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Childhood and adolescent lymphoid and myeloid leukaemia. Hematology Am Soc Hematol Educ Progr. 2004;1:118–45.
57.
Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukaemia with a normal karyotype. N Engl J Med. 2005;352(3):254–66.CrossRefPubMed
58.
Gale RE, Hills R, Kottaridis PD, Srirangan S, Wheatley K, Burnett AK, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukaemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukaemia, from the UK MRC AML10 and 12 trials. Blood. 2005;106(10):3658–65.CrossRefPubMed
59.
Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol. 2002;118(2):385–400.CrossRefPubMed
60.
Ofran Y, Rowe JM. Acute myeloid leukaemia in adolescents and young adults: challenging aspects. Acta Haematol. 2014;132(3–4):292–7.CrossRefPubMed
61.
Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Pediatric chronic myeloid leukaemia is a unique disease that requires a different approach. Blood. 2016;127(4):748–57.
62.
Kantarjian H, O’Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, et al. Improved survival in chronic myeloid leukaemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119(9):1981–7.CrossRefPubMedPubMedCentral
63.
de la Fuente J, Baruchel A, Biondi A, de Bont E, Dresse MF, Suttorp M, et al. Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol. 2014;167(1):33–47.CrossRefPubMed
64.
Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. Cancer incidence in five continents, vol. IX. Lyon: IARC Scientific Publications No. 160; 2007.
65.
Jaffe ES, Harris NL, Stein H, Vardiman J. World Health Organisation classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
66.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. World Health Organisation classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: WHO; 2008.
67.
Rossig C, Juergens H, Schrappe M, Moericke A, Henze G, von Stackelberg A, et al. Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria. Pediatr Blood Cancer. 2013;60(10):1574–81.CrossRefPubMed
68.
Vassal G, Fitzgerald E, Schrappe M, Arnold F, Kowalczyk J, Walker D, et al. Challenges for children and adolescents with cancer in Europe: the SIOP-Europe agenda. Pediatr Blood Cancer. 2014;61(9):1551–7.CrossRefPubMed
69.
70.
Metadata
Title
Incidence and survival time trends for Spanish children and adolescents with leukaemia from 1983 to 2007
Authors
R. Marcos-Gragera
J. Galceran
C. Martos
A. L. de Munain
M. Vicente-Raneda
C. Navarro
J. R. Quirós-Garcia
M.-J. Sánchez
E. Ardanaz
M. Ramos
A. Mateos
D. Salmerón
S. Felipe
R. Peris-Bonet
Publication date
01-03-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 3/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1531-z

Other articles of this Issue 3/2017

Clinical and Translational Oncology 3/2017 Go to the issue

Review Article

Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI)

Research Article

Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs

Review Article

Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?

Research Article

Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib

Editorial

The oncology day hospital in Spain: an updated analysis of Spanish Society of Medical Oncology (SEOM) looking forward

Research Article

Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits